Amgen, Inc. (AMGN) Holdings Reduced by Profund Advisors LLC

Profund Advisors LLC decreased its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 13.6% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 271,884 shares of the medical research company’s stock after selling 42,660 shares during the period. Amgen comprises 1.8% of Profund Advisors LLC’s portfolio, making the stock its 7th biggest holding. Profund Advisors LLC’s holdings in Amgen were worth $46,351,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Barrow Hanley Mewhinney & Strauss LLC raised its stake in shares of Amgen by 110.7% in the fourth quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 647 shares of the medical research company’s stock valued at $113,000 after acquiring an additional 340 shares during the last quarter. Cornerstone Advisors Inc. raised its stake in shares of Amgen by 76.5% in the first quarter. Cornerstone Advisors Inc. now owns 729 shares of the medical research company’s stock valued at $124,000 after acquiring an additional 316 shares during the last quarter. Taylor Hoffman Wealth Management bought a new position in shares of Amgen in the fourth quarter valued at approximately $127,000. Welch Group LLC bought a new position in shares of Amgen in the fourth quarter valued at approximately $148,000. Finally, Watermark Asset Management Inc. raised its stake in shares of Amgen by 8,481.8% in the fourth quarter. Watermark Asset Management Inc. now owns 944 shares of the medical research company’s stock valued at $164,000 after acquiring an additional 933 shares during the last quarter. Hedge funds and other institutional investors own 78.35% of the company’s stock.

Amgen opened at $185.07 on Wednesday, Marketbeat Ratings reports. The company has a debt-to-equity ratio of 2.14, a current ratio of 3.88 and a quick ratio of 3.60. Amgen, Inc. has a fifty-two week low of $161.13 and a fifty-two week high of $201.23. The company has a market capitalization of $122.16 billion, a P/E ratio of 14.71, a P/E/G ratio of 2.30 and a beta of 1.38.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, April 24th. The medical research company reported $3.47 earnings per share for the quarter, topping the consensus estimate of $3.24 by $0.23. Amgen had a net margin of 9.67% and a return on equity of 35.80%. The firm had revenue of $5.55 billion during the quarter, compared to analysts’ expectations of $5.44 billion. During the same quarter in the previous year, the company posted $3.15 EPS. Amgen’s revenue was up 1.6% on a year-over-year basis. sell-side analysts forecast that Amgen, Inc. will post 13.63 EPS for the current fiscal year.

In other Amgen news, EVP Sean E. Harper sold 1,525 shares of Amgen stock in a transaction on Tuesday, June 12th. The shares were sold at an average price of $184.27, for a total transaction of $281,011.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold a total of 6,100 shares of company stock valued at $1,099,220 in the last ninety days. Company insiders own 0.27% of the company’s stock.

A number of research analysts have recently issued reports on AMGN shares. TheStreet upgraded shares of Amgen from a “c+” rating to a “b-” rating in a research note on Friday, May 25th. Mizuho set a $200.00 target price on shares of Amgen and gave the company a “buy” rating in a research note on Tuesday, May 15th. Zacks Investment Research upgraded shares of Amgen from a “hold” rating to a “buy” rating and set a $194.00 target price for the company in a research note on Thursday, April 5th. Cowen reiterated a “buy” rating and issued a $204.00 target price on shares of Amgen in a research note on Tuesday, April 24th. Finally, Cann reiterated a “buy” rating on shares of Amgen in a research note on Friday, June 8th. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and ten have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $193.08.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply